跳至主要内容

Pregnancy Obesity Alters Fetal Liver Epigenetics and Metabolic Pathways

 Could a mother’s diet and excess weight during pregnancy predispose her offspring to become obese and develop metabolic disorders and cardiovascular diseases later in life? U.S. researchers report on new molecular and genetic studies in baboons that support existing epidemiological evidence suggesting that maternal obesity (MO) may “preprogram” offspring to develop cardiometabolic diseases in adulthood by causing changes in key metabolic pathways in the developing fetal liver.

In the field of metabolic diseases, we are proud of our portfolio of stable and effective animal models, especially those for Non-alcoholic Fatty Liver Disease (NAFLD). Though popular recently, they still lack effective drug treatment.

The results showed that baboon fetuses of obese baboon mothers who consume high-sugar, high-fat diets during pregnancy develop a fatty liver and exhibit significant metabolic disruption in the liver, including changes to gene expression profiles and epigenetic modifications.

“It wasn’t until we saw the microscope slides for the staining of liver sections showing very high amounts of lipid in fetuses of obese mothers that we realized the dramatic impact of maternal obesity at such an early developmental time point,” comments Peter Nathanielsz, M.D., Ph.D., at the University of Wyoming, Department of Animal Science, Laramie, WY. “Histological analyses of these livers showing the condition steatosis underlined the detrimental impact of MO on the developing fetus.”

The study results, published in The Journal of Physiology, are reported by the University of Wyoming researchers and collaborators at the Texas Biomedical Research Institute, Wake Forest Baptist Medical Center, Indiana University School of Medicine, and the University of Texas Health Science Center. Their paper is entitled “Primate Fetal Hepatic Responses to Maternal Obesity: Epigenetic Signalling Pathways and Lipid Accumulation.”  

Approximately 64% of women of childbearing age in the U.S.  are now either overweight or obese, the researchers report. Previous research in multiple species has linked maternal obesity and excess maternal weight with increased risk of obesity in their offspring and demonstrated that MO causes “developmental programming” effects, which predispose offspring to develop cardiometabolic disorders later in life.

“In light of these studies, we hypothesized that MO would induce epigenetic changes in fetal baboon (Papio hamadryas) liver resulting in dysregulation of key metabolic pathways that impact lipid metabolism,” the authors state. They devised a series of studies to evaluate the effects of pre-existing maternal obesity and a high-fat, high-sugar diet during pregnancy in baboons on the developing fetal liver, and in particular on gene expression, resulting  microRNA (miRNA) expression, and signaling pathways. “This is the first study where unbiased transcriptome analysis, including gene expression and miRNA expression, has been used to identify potential miRNA epigenetic regulators of metabolic disruption in nonhuman primate fetal MO livers,” the researchers claim.

Their results showed that the livers of fetuses developing in obese mothers accumulated three times as much lipid than control fetuses in nonobese mothers fed on a normal diet. “Our results showing increased lipid accumulation in MO baboon fetal liver suggest that these offspring are on an early trajectory to develop NAFLD [nonalcoholic fatty liver disease] and NASH [nonalcoholic steatohepatitis],” the authors write.

Gene expression profiling showed that maternal obesity also led to altered expression of fetal hepatic genes that are central to metabolism. This included dysregulation of the tricarboxylic acid (TCA) cycle, proteasome, oxidative phosphorylation, glycolysis, and Wnt/ß-catenin signaling pathways. “These well-characterized, inter-connected pathways have been shown to be important for liver metabolic function,” the authors state. The TCA cycle and oxidative phosphorylation are both central to the production of energy in the form of ATP. The proteasome is a multicatalytic enzyme complex, which plays an important role in degradation of both normal and damaged proteins, while the he Wnt/β-catenin signaling pathway plays an important role in development, tissue homeostasis, and oxidative stress, and is involved in the development of hepatic fibrosis and hepatocellular carcinoma.

Quantitative miRNA analysis of fetal livers indicated that altered epigenetic mechanisms may underpin metabolic pathway dysregulation. The analysis initially identified 67 miRNAs that were differentially expressed between the livers of fetuses in obese and nonobese mothers. Further prioritization honed this initial list down to 11 miRNAs targeting 13 genes in the affected pathways. “…fetal hepatic miRNA-gene interactions suggest that MO influences these interconnected pathways regulating cell proliferation, liver steatosis, hepatic fibrosis, and lipid  metabolism through epigenetic mechanisms,” the team writes. “These miRNA-gene interactions suggest important early molecular mechanism by which MO programs fetal hepatic lipid metabolism.”

The researchers aim to investigate the metabolic and cardiovascular health of monkey offspring of obese mothers, including liver function, at intervals throughout life, with a view to gaining new insights into whether the consequences of maternal obesity may even pass down to grandchildren. “Further studies are required in MO postnatal offspring to determine the extent to which the fetal phenotype persists, and the degree to which this increases offspring risk of cardiometabolic disorders in later life,” they note.

“This research is important as throughout the world over 50% of women of reproductive age are overweight or obese,” Nathanielsz states. “Maternal obesity, combined with high-fat, high-sugar diets, makes it more likely that children will suffer from liver disease and face health problems such as obesity and heart disease later in life.”

评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati